Generate Biomedicines, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data) (unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Collaboration revenue | $6,314 | $10,130 | $13,538 | $18,948 |
| Operating expenses: | ||||
| Research and development(1) | 64,330 | 59,735 | 122,142 | 106,560 |
| General and administrative(2) | 13,598 | 10,545 | 27,122 | 20,692 |
| Total operating expenses | 77,928 | 70,280 | 149,264 | 127,252 |
| Loss from operations | (71,614) | (60,150) | (135,726) | (108,304) |
| Other income (expense), net | ||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363) | — |
| Interest expense | (155) | (307) | (337) | (675) |
| Interest income | 4,629 | 3,789 | 7,542 | 8,070 |
| Foreign currency exchange loss | (62) | (30) | (4) | (47) |
| Total other income (expense), net | 4,412 | 3,452 | 6,838 | 7,348 |
| Loss before provision for income taxes | (67,202) | (56,698) | (128,888) | (100,956) |
| Provision for income taxes | (53) | (44) | (81) | (100) |
| Net loss | (67,255) | (56,742) | (128,969) | (101,056) |
| Net loss attributable to non-controlling interests | — | (4,313) | (268) | (6,942) |
| Net loss attributable to Generate Biomedicines, Inc. stockholders | (67,255) | (52,429) | (128,701) | (94,114) |
| Convertible preferred stock accrued dividends | — | (11,593) | (7,749) | (23,185) |
| Net loss attributable to Generate Biomedicines, Inc. common stockholders | $(67,255) | $(64,022) | $(136,450) | $(117,299) |
| Net loss per share, basic and diluted | $(0.52) | $(1.94) | $(1.41) | $(3.57) |
| Weighted average common shares outstanding, basic and diluted | 128,240,371 | 32,996,506 | 96,730,886 | 32,894,770 |
| Other comprehensive loss: | ||||
| Net loss | (67,255) | (56,742) | (128,969) | (101,056) |
| Unrealized loss on marketable securities | (153) | (57) | (235) | (128) |
| Comprehensive loss | $(67,408) | $(56,799) | $(129,204) | $(101,184) |
| Comprehensive loss attributable to non-controlling interest | — | (4,313) | (268) | (6,942) |
| Comprehensive loss attributable to Generate Biomedicines, Inc. stockholders | $(67,408) | $(52,486) | $(128,936) | $(94,242) |
(1)
Includes related party amounts of $0.1 million for the six months ended June 30, 2026, and $0.1 million and $0.3 million for the three and six months ended June 30, 2025. See Note 14 for details of related party amounts.
(2)
Includes related party amounts of $0.1 million and $0.2 million for the three and six months ended June 30, 2026, and $0.1 million and $0.3 million for the three and six months ended June 30, 2025. See Note 14 for details of related party amounts.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.